[go: up one dir, main page]

CA2383794A1 - Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee - Google Patents

Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee Download PDF

Info

Publication number
CA2383794A1
CA2383794A1 CA002383794A CA2383794A CA2383794A1 CA 2383794 A1 CA2383794 A1 CA 2383794A1 CA 002383794 A CA002383794 A CA 002383794A CA 2383794 A CA2383794 A CA 2383794A CA 2383794 A1 CA2383794 A1 CA 2383794A1
Authority
CA
Canada
Prior art keywords
antineoplastic agent
composition
hemi
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383794A
Other languages
English (en)
Inventor
Dominique P. Bridon
Roger Leger
Xicai Huang
Peter G. Milner
Alan M. Ezrin
Damon Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383794A1 publication Critical patent/CA2383794A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)

Abstract

L'invention concerne la préparation de dérivés d'agents anticancéreux. Ces dérivés sont capables de former des liaisons covalentes avec un ou plusieurs composants sanguins, de préférence avec un composant sanguin mobile.
CA002383794A 1999-09-07 2000-09-07 Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee Abandoned CA2383794A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15268199P 1999-09-07 1999-09-07
US60/152,681 1999-09-07
PCT/IB2000/001427 WO2001017614A2 (fr) 1999-09-07 2000-09-07 Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee

Publications (1)

Publication Number Publication Date
CA2383794A1 true CA2383794A1 (fr) 2001-03-15

Family

ID=22543945

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002383798A Abandoned CA2383798A1 (fr) 1999-09-07 2000-09-07 Diffusion pulmonaire permettant la bioconjugaison
CA002383794A Abandoned CA2383794A1 (fr) 1999-09-07 2000-09-07 Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002383798A Abandoned CA2383798A1 (fr) 1999-09-07 2000-09-07 Diffusion pulmonaire permettant la bioconjugaison

Country Status (5)

Country Link
EP (2) EP1212120A2 (fr)
JP (2) JP2003508501A (fr)
AU (3) AU7440400A (fr)
CA (2) CA2383798A1 (fr)
WO (2) WO2001017614A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2002066511A2 (fr) 2001-02-16 2002-08-29 Conjuchem Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
WO2002094242A1 (fr) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Administration de rizatriptan ou de zolmitriptan par voie d'inhalation
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2446904A1 (fr) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
SG165988A1 (en) * 2001-11-29 2010-11-29 Theracos Inc Compounds for treatment of inflammation, diabetes and related disorders
AU2003246500A1 (en) * 2002-07-31 2004-02-16 Conjuchem Biotechnologies Inc. Long lasting natriuretic peptide derivatives
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
CA2520392C (fr) * 2003-03-26 2014-08-12 Sudhir Paul Fixation par liaison covalente de ligands a des proteines nucleophiles dirigees par une liaison non covalente
US20040234914A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
DE10356346A1 (de) * 2003-11-28 2005-06-23 TransMIT Gesellschaft für Technologietransfer mbH Erfindung betreffend Prophylaxe und Therapie von Erkrankungen, die durch Thrombusbildung verusacht oder mit versacht werden
CN101137326B (zh) * 2003-12-01 2010-10-20 医疗物理有限公司 肾上腺素能成像剂和肾上腺素能干扰剂的应用及相关试剂盒
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1781360A1 (fr) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Dispositif de distribution de drogue par aérosol intégrant des conditionnements thermiques actionnés par percussion
EP2374480A3 (fr) * 2005-08-19 2013-05-01 Endocyte, Inc. Conjugués de ligands multi-médicaments
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
WO2008047241A2 (fr) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Peptides du facteur libérateur de corticotrophine modifiés et leurs utilisations
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
CN101754747A (zh) * 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
WO2010068754A2 (fr) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Procédés et compositions pour la délivrance de médicaments aux poumons
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
MX2020007997A (es) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Dispositivo electrico de aerosol de condensacion.
MX2020009950A (es) 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
BR112021022225A2 (pt) * 2019-05-06 2021-12-28 Centre Nat Rech Scient Composto, pró-droga e composição farmacêutica
CN111138435A (zh) * 2020-01-08 2020-05-12 宜昌博仁凯润药业有限公司 一种修饰过的甲氨蝶呤及其制备方法和应用
CR20230530A (es) 2021-05-13 2024-02-19 Carmot Therapeutics Inc Moduladores de los receptores acoplados a proteínas g.
CN117551062B (zh) * 2023-11-07 2025-12-16 江苏吉贝尔药业股份有限公司 一种紫杉烷衍生物及其制备方法、应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138430A (ja) * 1985-12-12 1987-06-22 Teijin Ltd メソトレキセ−トと蛋白質の結合体の製造方法
JPH01211530A (ja) * 1988-02-16 1989-08-24 Pola Chem Ind Inc 抗腫瘍剤
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DE69626849T2 (de) * 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
CA2264227A1 (fr) * 1996-09-27 1998-04-02 Raymond A. Firestone Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques
AU748496B2 (en) * 1998-03-23 2002-06-06 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung

Also Published As

Publication number Publication date
JP2003508502A (ja) 2003-03-04
WO2001017568A3 (fr) 2002-07-11
AU7440400A (en) 2001-04-10
AU2005203768A1 (en) 2005-09-15
EP1235618A2 (fr) 2002-09-04
CA2383798A1 (fr) 2001-03-15
WO2001017614A3 (fr) 2002-02-28
AU781380B2 (en) 2005-05-19
JP2003508501A (ja) 2003-03-04
WO2001017614A2 (fr) 2001-03-15
WO2001017568A2 (fr) 2001-03-15
AU7440600A (en) 2001-04-10
EP1212120A2 (fr) 2002-06-12

Similar Documents

Publication Publication Date Title
CA2383794A1 (fr) Methodes et compositions destinees a la production d'agents anticancereux a activite prolongee
US5667764A (en) Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US20220105191A1 (en) Bioorthogonal compositions
CA2124329C (fr) Composes, compositions et methodes de fixation de substances bio-actives aux membranes de surface de bio-particules
US6310039B1 (en) Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
KR102612882B1 (ko) 이관능성 킬레이트 및 그의 용도의 약동학적 증진
JP2022506299A (ja) インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート
EP0354729A2 (fr) Conjugués de médicaments cytotoxiques
Kratz et al. Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy
JP2002518405A (ja) ビタミンｂ１２誘導体及びそれらの製造方法
JP2022552757A (ja) カンプトテシン類医薬品及びその抗体複合体
CN120882720A (zh) 依喜替康衍生物及其抗体药物偶联物
CN110759940B (zh) 连接子、含连接子的抗体偶联药物及连接子的用途
CN116870176B (zh) PSMA靶向的PSMA-PARPi偶联物及制备方法和应用
EP1889639A2 (fr) Procédés et compositions pour produire des agents antinéoplastiques de très longue durée
US20090324489A1 (en) Wortmannin conjugates and uses thereof
WO2023220280A1 (fr) Lieurs conjugués à un médicament clivés par rayonnement permettant une sclérose en plaques à libération de charge utile locale
CN118697897B (zh) 多肽偶联药物及其制备方法和应用
CN119607217B (zh) 一种核酸适体激动剂偶联物及其制备方法和应用
US20250049936A1 (en) Bioorthogonal compositions
CN118852143A (zh) 一种蛋白质冠主动调控型药物化合物及其应用
CN119798356A (zh) 一种紫杉醇分子伞递送系统前药及其制备方法和应用
CN119529008A (zh) 吉西他滨前药及其制备方法与应用
HK40031527B (zh) 双官能螯合物的药代动力学增强及其用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead